# A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia

> **NCT01051531** · PHASE3 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 546 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Paliperidone palmitate

## Key facts

- **NCT ID:** NCT01051531
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-04-22
- **Primary completion:** 2013-05-17
- **Final completion:** 2013-05-17
- **Target enrollment:** 546 (ACTUAL)
- **Last updated:** 2024-10-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01051531

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01051531, "A Safety, Tolerability, and Treatment Response Study of Paliperidone Palmitate Administered to Patients With Schizophrenia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01051531. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*